Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paricalcitol Over Vessel Wall

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 50 and 75 years.~* Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).~* Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.~* Plasma concentrations of 25 (OH) vitamin D \<30 ng/ml.~* Without vitamin D supplementation for 3 months before the study.~* Serum P\> 3.8 mg / dl.~* Serum Ca\> 9.8 mg / dl.~* No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).~* No exclusion criteria for the use of contrast.~Exclusion Criteria:~* Allergic reaction to sulfur hexafluoride.~* Recent unstable cardiac symptoms.~* Patients with recent coronary intervention (\<7 days)~* Patients with class III and IV heart failure or severe arrhythmias.~* Severe pulmonary hypertension.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patient will take one pill of paricalcitol a day.
- Usual treatment. (Type: NO_INTERVENTION): Patient allocated to this arm will only take his/her habitual treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).